Dare Bioscience (NASDAQ:DARE) Announces Earnings Results

Dare Bioscience (NASDAQ:DARE) announced its earnings results on Thursday. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.42, FiscalAI reports. The firm had revenue of $1.02 million during the quarter, compared to analyst estimates of $0.75 million.

Here are the key takeaways from Dare Bioscience’s conference call:

• DARE to PLAY is available for pre-fulfillment prescriptions nationwide with telehealth access, and the company expects dispensing and initial product revenue to begin in Q2 2026.
• Management highlights clinical and manufacturing differentiation—DARE to PLAY is the only topical sildenafil cream with published clinical data (increased genital blood flow in 10–15 minutes) and GMP production for consistent potency and quality.
• Multiple near‑term pipeline catalysts could drive value, including Flora Sync LF5 consumer availability in Q2 2026, Ovaprene phase III enrollment completion expected in 2026 (potential 2027 data readout), and DARE‑HPV advancing to phase II this year with ARPA‑H funding.
• Financially, the company reported $24.7 million in cash and approximately $3.4 million in working capital as of Dec 31, 2025, supplemented by significant non‑dilutive grant funding, while management emphasizes near‑term revenue as dispensing scales.

Dare Bioscience Stock Up 2.6%

Shares of Dare Bioscience stock opened at $1.55 on Friday. Dare Bioscience has a 1 year low of $1.27 and a 1 year high of $9.19. The company has a market cap of $22.15 million, a P/E ratio of -1.24 and a beta of 0.96. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average price of $1.65 and a 200 day moving average price of $1.88.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DARE shares. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Dare Bioscience in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On Dare Bioscience

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in shares of Dare Bioscience in the third quarter worth approximately $37,000. Raymond James Financial Inc. grew its position in Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 13,650 shares in the last quarter. Finally, LPL Financial LLC acquired a new position in Dare Bioscience in the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.